Sandoz Eyes Doubling Of Japan Business Despite Price Pressures
Executive Summary
Sandoz is bullish on the prospects for its Japanese business, helped by an operating environment it sees as favoring generics and biosimilars and despite growing cost control pressures.
You may also be interested in...
Billions At Stake As Generic Approvals Open Up Japan Big Sellers
Japan has approved a new batch of first-time and other generic drugs that will be reimbursed and launched in June, putting at risk several billion dollars’ worth of combined sales of some major branded products.
Billions At Stake As Generic Approvals Open Up Japan Big Sellers
Japan has approved a new batch of first-time and other generic drugs that will be reimbursed and launched in June, putting at risk several billion dollars’ worth of combined sales of some major branded products.
FDA Claims Sole Authority Over Naming Of US-Licensed Biologics
Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.